ATE311187T1 - (2-imidazolin-2-ylamino)quinoxaline zur behandlung von neuralen verletzungen - Google Patents
(2-imidazolin-2-ylamino)quinoxaline zur behandlung von neuralen verletzungenInfo
- Publication number
- ATE311187T1 ATE311187T1 AT00906868T AT00906868T ATE311187T1 AT E311187 T1 ATE311187 T1 AT E311187T1 AT 00906868 T AT00906868 T AT 00906868T AT 00906868 T AT00906868 T AT 00906868T AT E311187 T1 ATE311187 T1 AT E311187T1
- Authority
- AT
- Austria
- Prior art keywords
- quinoxaline
- ylamino
- imidazoline
- treatment
- hydrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/225,036 US6194415B1 (en) | 1995-06-28 | 1999-01-04 | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
PCT/US2000/000068 WO2000040245A1 (en) | 1999-01-04 | 2000-01-04 | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating neural injury |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE311187T1 true ATE311187T1 (de) | 2005-12-15 |
Family
ID=22843255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00906868T ATE311187T1 (de) | 1999-01-04 | 2000-01-04 | (2-imidazolin-2-ylamino)quinoxaline zur behandlung von neuralen verletzungen |
Country Status (12)
Country | Link |
---|---|
US (6) | US6194415B1 (de) |
EP (1) | EP1146877B1 (de) |
JP (2) | JP2002534387A (de) |
CN (1) | CN1205932C (de) |
AT (1) | ATE311187T1 (de) |
AU (1) | AU762641B2 (de) |
BR (1) | BR0007394A (de) |
CA (1) | CA2357014C (de) |
DE (1) | DE60024407T2 (de) |
ES (1) | ES2251968T3 (de) |
HK (1) | HK1040938B (de) |
WO (1) | WO2000040245A1 (de) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856329A (en) * | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
US6294553B1 (en) | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
US6638239B1 (en) * | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
US20020143284A1 (en) * | 2001-04-03 | 2002-10-03 | Hosheng Tu | Drug-releasing trabecular implant for glaucoma treatment |
US20040111050A1 (en) * | 2000-04-14 | 2004-06-10 | Gregory Smedley | Implantable ocular pump to reduce intraocular pressure |
AU2006201701B2 (en) * | 2000-11-01 | 2007-07-12 | Allergan, Inc. | Methods and compositions for treatment of ocular neovascularization and neural injury |
US20030082183A1 (en) * | 2000-11-01 | 2003-05-01 | Wheeler Larry A. | Methods and compositions for treatment of ocular neovascularization and neural injury |
WO2002058730A2 (en) * | 2000-11-01 | 2002-08-01 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
US7431710B2 (en) * | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
EP2982354A1 (de) | 2001-04-07 | 2016-02-10 | Glaukos Corporation | System zur behandlung von augenstörungen |
US7678065B2 (en) * | 2001-05-02 | 2010-03-16 | Glaukos Corporation | Implant with intraocular pressure sensor for glaucoma treatment |
AU2002305400A1 (en) * | 2001-05-03 | 2002-11-18 | Glaukos Corporation | Medical device and methods of use for glaucoma treatment |
US20020198209A1 (en) * | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
US6838074B2 (en) | 2001-08-08 | 2005-01-04 | Bristol-Myers Squibb Company | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent |
US7331984B2 (en) * | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
US7163543B2 (en) * | 2001-11-08 | 2007-01-16 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US6761694B2 (en) | 2001-12-13 | 2004-07-13 | Allergan, Inc. | Methods for measuring retinal damage |
AU2003209297A1 (en) * | 2002-01-18 | 2003-09-02 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
US7030149B2 (en) * | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
US7642258B2 (en) * | 2002-04-19 | 2010-01-05 | Allergan, Inc. | Combination of brimonidine and timolol for topical ophthalmic use |
US20040266776A1 (en) * | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
EP1549314B1 (de) * | 2002-10-08 | 2007-12-12 | Allergan, Inc. | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson |
ES2322954T3 (es) * | 2002-10-08 | 2009-07-02 | Allergan, Inc. | Agonistas del adrenoceptor alfa 2b o 2b/2c para el tratamiento de la enfermedad de alzheimer y la enfermedad de parkinson. |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US20050020600A1 (en) | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
WO2005115395A2 (en) | 2004-05-25 | 2005-12-08 | Sansrosa Pharmaceutical Development, Inc. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
EP2119439A3 (de) * | 2005-05-17 | 2010-01-27 | Santen Pharmaceutical Co., Ltd. | Angiogenese-Hemmer zur Behandlung von Makuladegeneration |
WO2007019427A2 (en) * | 2005-08-08 | 2007-02-15 | Massachusetts Eye & Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US7534795B2 (en) * | 2005-10-25 | 2009-05-19 | Allergan, Inc. | Compounds and their use related to compositions for treating disease |
NZ568694A (en) | 2005-11-09 | 2011-09-30 | Zalicus Inc | Method, compositions, and kits for the treatment of medical conditions |
US7850431B2 (en) * | 2005-12-02 | 2010-12-14 | Entegris, Inc. | System and method for control of fluid pressure |
JP5748407B2 (ja) | 2006-11-10 | 2015-07-15 | グローコス コーポレーション | ブドウ膜強膜シャント |
US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
US20080293728A1 (en) * | 2007-05-18 | 2008-11-27 | Mcintire Gregory L | Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions |
WO2009003193A1 (en) * | 2007-06-27 | 2008-12-31 | Brooks Automation, Inc. | Position feedback for self bearing motor |
US8283813B2 (en) * | 2007-06-27 | 2012-10-09 | Brooks Automation, Inc. | Robot drive with magnetic spindle bearings |
US9752615B2 (en) * | 2007-06-27 | 2017-09-05 | Brooks Automation, Inc. | Reduced-complexity self-bearing brushless DC motor |
CA2709199A1 (en) | 2007-12-21 | 2009-07-02 | Galderma Laboratories, Inc. | Pre-surgical treatment |
US20090291073A1 (en) * | 2008-05-20 | 2009-11-26 | Ward Keith W | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same |
US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
JP5671459B2 (ja) | 2008-08-01 | 2015-02-18 | アイ・セラピーズ・エル・エル・シー | 血管収縮組成物および使用方法 |
US20100203165A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
US8034813B2 (en) | 2008-11-18 | 2011-10-11 | Bausch & Lomb Incorporated | Polymorphs of brimonidine pamoate |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
CA2780267C (en) | 2009-11-09 | 2020-06-30 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
WO2011060104A2 (en) | 2009-11-10 | 2011-05-19 | Allegro Pharmaceuticals, Inc. | Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites |
US11673914B2 (en) | 2009-11-10 | 2023-06-13 | Allegro Pharmaceuticals, LLC | Peptide therapies for reduction of macular thickening |
EP2329849B1 (de) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Kombination aus einem Alpha-2-Adrenozeptor-Agonisten und einem nichtsteroidalen entzündungshemmenden Mittel zur Behandlung oder Prävention einer Entzündungskrankheit der Haut |
US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
CA2782872A1 (en) * | 2009-12-17 | 2011-06-23 | Alpha Synergy Development, Inc. | Compositions and methods for ophthalmic delivery of nasal decongestants |
US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
HUE033143T2 (en) | 2010-03-26 | 2017-11-28 | Galderma Res & Dev | Preparations containing brimonidine for the treatment of erythema |
WO2011117378A2 (en) | 2010-03-26 | 2011-09-29 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of telangiectasia |
CN104288768A (zh) | 2010-06-30 | 2015-01-21 | 盖尔德马研究及发展公司 | α2-肾上腺素能受体激动剂的用途 |
CN103209690A (zh) | 2010-06-30 | 2013-07-17 | 盖尔德马研究及发展公司 | α肾上腺素能受体激动剂用于预防或治疗皮肤肿瘤的用途 |
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
RS53531B1 (en) | 2010-10-21 | 2015-02-27 | Galderma S.A. | BRIMONIDINE GEL COMPOSITION |
US8445526B2 (en) | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
US11363951B2 (en) | 2011-09-13 | 2022-06-21 | Glaukos Corporation | Intraocular physiological sensor |
BR112014009209A2 (pt) | 2011-10-19 | 2017-04-18 | Galderma Sa | método para o tratamento de hemangiomas capilares em um ser humano |
WO2013057579A2 (en) | 2011-10-19 | 2013-04-25 | Galderma Pharma S.A. | Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors |
WO2014127243A1 (en) | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Sustained drug delivery implant |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
US8999938B2 (en) | 2013-06-21 | 2015-04-07 | Gnt Llc | Ophthalmic lipophilic drug delivery vehicle formulations |
CN105658221B (zh) | 2013-09-26 | 2022-05-10 | 高德美国际公司 | 用于治疗萎缩性皮肤瘢痕形成的前列腺素F2α及其类似物 |
US20180207227A1 (en) * | 2017-01-19 | 2018-07-26 | Allegro Pharmaceuticals, Inc. | Therapeutic and Neuroprotective Peptides |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
US4029792A (en) | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
US5180721A (en) | 1989-05-22 | 1993-01-19 | Allergan, Inc. | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure |
US5077292A (en) | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
US5021416A (en) * | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
US5215991A (en) | 1990-01-26 | 1993-06-01 | Allergan, Inc. | Combination of selective alpha-adrenergic agonists and Na+ /H+ ex |
EP0735877B1 (de) | 1993-12-17 | 2000-07-19 | The Procter & Gamble Company | 6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten |
WO1996013267A2 (en) | 1994-10-27 | 1996-05-09 | Allergan | Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma |
US5856329A (en) * | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
WO1998018469A1 (fr) * | 1996-10-31 | 1998-05-07 | Nippon Shinyaku Co., Ltd. | Agents protecteurs des cellules des nerfs craniens |
-
1999
- 1999-01-04 US US09/225,036 patent/US6194415B1/en not_active Expired - Lifetime
-
2000
- 2000-01-04 AU AU28460/00A patent/AU762641B2/en not_active Expired
- 2000-01-04 CN CNB008025266A patent/CN1205932C/zh not_active Expired - Lifetime
- 2000-01-04 CA CA002357014A patent/CA2357014C/en not_active Expired - Lifetime
- 2000-01-04 ES ES00906868T patent/ES2251968T3/es not_active Expired - Lifetime
- 2000-01-04 AT AT00906868T patent/ATE311187T1/de active
- 2000-01-04 BR BR0007394-6A patent/BR0007394A/pt not_active Application Discontinuation
- 2000-01-04 DE DE60024407T patent/DE60024407T2/de not_active Expired - Lifetime
- 2000-01-04 JP JP2000592002A patent/JP2002534387A/ja active Pending
- 2000-01-04 EP EP00906868A patent/EP1146877B1/de not_active Expired - Lifetime
- 2000-01-04 WO PCT/US2000/000068 patent/WO2000040245A1/en active IP Right Grant
- 2000-09-06 US US09/655,579 patent/US6248741B1/en not_active Expired - Fee Related
-
2001
- 2001-06-18 US US09/883,753 patent/US20010046998A1/en not_active Abandoned
-
2002
- 2002-02-22 US US10/080,451 patent/US6465464B2/en not_active Expired - Lifetime
- 2002-04-18 HK HK02102938.9A patent/HK1040938B/zh not_active IP Right Cessation
- 2002-06-03 US US10/162,088 patent/US20020183328A1/en not_active Abandoned
-
2005
- 2005-12-07 US US11/296,116 patent/US8455492B2/en not_active Expired - Lifetime
-
2007
- 2007-06-27 JP JP2007168778A patent/JP2007291129A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US6248741B1 (en) | 2001-06-19 |
HK1040938B (zh) | 2006-05-12 |
US20020183328A1 (en) | 2002-12-05 |
DE60024407D1 (de) | 2006-01-05 |
WO2000040245A1 (en) | 2000-07-13 |
BR0007394A (pt) | 2001-10-30 |
EP1146877B1 (de) | 2005-11-30 |
AU762641B2 (en) | 2003-07-03 |
JP2007291129A (ja) | 2007-11-08 |
DE60024407T2 (de) | 2006-08-10 |
US20020111357A1 (en) | 2002-08-15 |
EP1146877A1 (de) | 2001-10-24 |
CA2357014C (en) | 2009-08-04 |
US8455492B2 (en) | 2013-06-04 |
AU2846000A (en) | 2000-07-24 |
US6194415B1 (en) | 2001-02-27 |
JP2002534387A (ja) | 2002-10-15 |
US20010046998A1 (en) | 2001-11-29 |
CA2357014A1 (en) | 2000-07-13 |
HK1040938A1 (en) | 2002-06-28 |
CN1335773A (zh) | 2002-02-13 |
US20060089361A1 (en) | 2006-04-27 |
ES2251968T3 (es) | 2006-05-16 |
US6465464B2 (en) | 2002-10-15 |
CN1205932C (zh) | 2005-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60024407D1 (de) | (2-imidazolin-2-ylamino)quinoxaline zur behandlung von neuralen verletzungen | |
ATE322267T1 (de) | Verwendung von (2-imidazolin-2-yl- amino)quinoxalinen zur behandlung von augennerfverletzung | |
BR9814116A (pt) | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico | |
DE69823344D1 (de) | Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen | |
YU69003A (sh) | Aril i heteroaril urea chk1 inhibitori kao jedinjenja koja povećavaju osetljivost na radioterapiju i hemoterapiju | |
DE69329727D1 (de) | Neue imidazol derivate, ihre herstellung und therapeutische verwendung | |
BR0011674A (pt) | Cristal, composição farmacêutica, método para tratar ou prevenir úlcera digestiva em um mamìfero em necessidade deste, e, uso do cristal | |
AR012660A1 (es) | Uso de compuestos de quinazolina para la manufactura de un medicamento util para el tratamiento de enfermedades poliquisticas del rinon. | |
TR199802296T2 (xx) | Yeni 2,3 dis�bstit�te-4 (3H)-kinazolinonlar | |
ATE323686T1 (de) | Substituierte 2-arylbenzazole und ihre verwendung als antitumorale mittel | |
ES2105617T3 (es) | Derivados de piperacina como antagonistas de 5-ht. | |
KR880009948A (ko) | 항 알레르기 및 항 염증제로서 용도를 갖는 신규의 나프탈렌 유도체 | |
ATE246184T1 (de) | Chinoline und deren therapeutische verwendung | |
NO963706L (no) | Benzenkondenserte heterosykliske derivater og deres anvendelse | |
WO2001012169A3 (en) | Method of cancer treatment | |
NZ512981A (en) | Use of pyridazino[4,5-b]indole-1-acetamide derivatives for treating diseases related to the dysfunction of peripheral benzodiazepine receptors | |
DE69819742D1 (de) | Indolderivate als 5-ht1b und 5-ht1d agonisten | |
KR950703339A (ko) | 질소 치환된 아크리딘의 대사를 억제하기 위한 시토크롬 P450 억제제의 용도(Use of Cytochrome P450 Inhibitors for Inhibiting he Metabolism of Nitrogen Substituted Acridine) | |
DE69708484D1 (de) | Pyridinderivate,als Arzneimittel zur Behandlung von Geschwüren und als antibakterielle Mittel | |
KR950002761A (ko) | 강박 반응 장애 치료제 제조용으로서의 n-(피리디닐)-1h-인돌-1-아민의 용도 | |
ATE279925T1 (de) | Verwendung von halofuginon zur herstellung eines medikaments zur vorbeugung von neovaskularisation und zur behandlung bösartiger tumore | |
ES8604843A1 (es) | Un metodo para la preparacion de un derivado de acetileno | |
ATE112569T1 (de) | Verwendung von imidazopyrazolderivaten als analgesische und antiinflammatorische mittel. | |
ATE227718T1 (de) | N-aryloxyethyl-indolyl-alkylamine zur behandlung von depressionen | |
AU758194C (en) | Novel benzimidazoles and benzoxazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1146877 Country of ref document: EP |